Moderna stock loses 10.43% in Xetra week

Published on 11/14/2026 at 10:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna stock faced a sharp weekly setback after the November 6 earnings update. The company returned to profit and lifted its 2026 revenue-growth outlook.

Profit recovery meets market pressure

Moderna returned to quarterly profitability as third-quarter revenue increased 29 percent.
Management raised its 2026 revenue-growth outlook to 15 percent to 25 percent.
Pipeline milestones and international vaccine demand remain central to the recovery case.

Moderna Inc., US60770K1079, Illustration mit AI erstellt.

Moderna stock lost 10.43 percent on Xetra between Friday, November 6, and Friday, November 13, closing the week at 206.45 euros. On Saturday, November 14, the stock traded at 200.60 euros on Lang & Schwarz at 10:45 CET, 2.83 percent below the Xetra close of Friday, November 13.

Profit recovery meets market pressure

On November 6, Moderna reported third-quarter revenue of 1.3 billion US dollars, up 29 percent year over year, and returned to profitability. The company's investor-relations update also said cash costs declined 10 percent to 1.0 billion US dollars.

Management raised its 2026 revenue-growth outlook to 15 percent to 25 percent, compared with a previous expectation of growth of up to 10 percent. Moderna also lifted its projected year-end cash and investments range to 8.1 billion to 8.3 billion US dollars from 4.7 billion to 5.2 billion US dollars.

Pipeline execution remains decisive

The improved financial outlook was accompanied by progress across the development portfolio. Moderna said its pivotal mRNA-3927 study had reached target enrollment, with data expected by year-end, while initial data from the mRNA-2808 multiple-myeloma program are scheduled for presentation at the American Society of Hematology meeting from December 12 to 15.

The Xetra closing prices show that the weekly decline followed a sharp reversal from the previous Friday's close. For investors, the recovery case therefore rests on whether stronger international vaccine demand and the clinical pipeline can support the higher outlook.